Barcelona, Spain
February 17 - February 18, 2007
Psoriasis is a chronic life-ruining disease with significant unmet clinical need in the management of patients. It affects between 1%-3% of the population worldwide and is accompanied by substantial physical and psychosocial distress.
Recent progress in understanding the pathogenesis of psoriasis has transformed psoriasis from a disease of keratinocyte hyperproliferation to that of T-cell mediated autoimmune disorder.
Since there is no cure for psoriasis, patients with moderate-to-severe plaque-type psoriasis often require lifelong therapy to control their disease. Traditional approaches such as PUVA, cyclosporine or methotrexate are problematic for long-term use because of inconvenience, organ toxicity, broad-band immunosuppression, drug interactions and a loss of efficacy over time.
Hence, there has been a demand for new therapeutic approaches that are more convenient, effective, safe, and immunologically selective. Numerous biological agents that modulate T cell and cytokine action at various steps along the pathogenic sequence have been developed and studied in clinical trials for the treatment of psoriasis. This symposia will aim to bring all the current knowledge together and provide the audience with a state-of-the-art view on how to improve management of patients with psoriasis.
LEARNING OBJECTIVES
After participating in this symposium, the participants will have knowledge in:
- Developments in psoriasis management
- Role of traditional systemic therapies and how it is changing
- New targeted biological therapies for psoriasis
- The integration of biological treatments into daily clinical practice
- Future developments in psoriasis
TARGET AUDIENCE
Clinicians and scientists involved in the management of psoriasis will benefit from the symposium.
Serono Symposia International Foundation (www.seronosymposia.org) will submit this program “Psoriasis: From Scientific Potential to Clinical Reality” (Barcelona, Spain, February 16–18, 2007) for accreditation by the European Accreditation Council for Continuing Medical Education (EACCME), by the Royal College of Physicians, and by the RIZIV, Belgium.
